Population Pharmacokinetic/ Pharmacodynamics of Interleukin-6 Receptor Inhibitor

Population Pharmacokinetic/ Pharmacodynamics of Interleukin-6 Receptor Inhibitor | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 6 April 2026 V1 Latest version Share on Population Pharmacokinetic/ Pharmacodynamics of Interleukin-6 Receptor Inhibitor Authors : Binyi Hu , xiangxing Liu , Liming Chen , Fan Huang , Qian Wang , Qun Gu , Yan-nan Zang , Lujin Li 0000-0003-2923-3206 , Rui Ding , Suping Niu , Hua Ye , and Yi Fang 0000-0002-3547-5829 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.177545916.60646367/v1 115 views 69 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Objective: Recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody is an innovative drug developed by China. In the clinical trial of healthy people, the innovative drug showed fairly good safety and tolerance. Model-informed drug development (MIDD) is widely used in innovative drug development. It has an important practical value in improving efficiency, predicting drug interactions, and optimizing dosage. Therefore, we aim at providing evidence and support for dose selection and dosing interval of the innovative drug. Methods: A population pharmacokinetics (PopPK) model, dose-exposure-response (D-E-R) analysis, and Monte Carlo simulation would be performed to explore covariates, optimal dose selection, and dosing interval recommendation. Results : Body weight and hemoglobin have an effect on apparent volume of distribution, total bilirubin has an effect on of clearance rate. D-E-R analysis presents that the innovative drug achieves benefit efficacy with 6 mg/kg. Monte Carlo simulation showed that administration every 4 weeks, 6 weeks and 8 weeks has similar drug exposure. Conclusion: Our results demonstrated that the innovative drug administration every 8 weeks with 6 mg/kg is appropriate. It is worth noting that further clinical trials with larger samples needs to be develop to confirm the results. Supplementary Material File (figure.docx) Download 2.64 MB File (manuscript(1).docx) Download 89.15 KB File (tables and figures.pdf) Download 777.29 KB Information & Authors Information Version history V1 Version 1 06 April 2026 Copyright This work is licensed under a Non Exclusive No Reuse License. Authors Affiliations Binyi Hu Xuzhou Medical University School of Pharmacy View all articles by this author xiangxing Liu Xuzhou Medical University School of Pharmacy View all articles by this author Liming Chen Peking University People's Hospital View all articles by this author Fan Huang Peking University People's Hospital View all articles by this author Qian Wang Peking University People's Hospital View all articles by this author Qun Gu Peking University People's Hospital View all articles by this author Yan-nan Zang Beijing Anding Hospital Capital Medical University View all articles by this author Lujin Li 0000-0003-2923-3206 Shanghai University of Traditional Chinese Medicine View all articles by this author Rui Ding Peking University People's Hospital View all articles by this author Suping Niu Peking University People's Hospital View all articles by this author Hua Ye Peking University People's Hospital Department of Rheumatology and Immunology View all articles by this author Yi Fang 0000-0002-3547-5829 [email protected] Xuzhou Medical University School of Pharmacy View all articles by this author Metrics & Citations Metrics Article Usage 115 views 69 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Binyi Hu, xiangxing Liu, Liming Chen, et al. Population Pharmacokinetic/ Pharmacodynamics of Interleukin-6 Receptor Inhibitor. Authorea . 06 April 2026. DOI: https://doi.org/10.22541/au.177545916.60646367/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.177545916.60646367/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9fe0b5705b494193',t:'MTc3OTE2ODYxNw=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();